Compare NUVB & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVB | INSP |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2020 | 2018 |
| Metric | NUVB | INSP |
|---|---|---|
| Price | $6.96 | $60.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 16 |
| Target Price | $11.38 | ★ $94.00 |
| AVG Volume (30 Days) | ★ 5.8M | 700.3K |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 71.56 | ★ 179.43 |
| EPS | ★ N/A | N/A |
| Revenue | $62,902,000.00 | ★ $82,050,000.00 |
| Revenue This Year | $203.82 | $8.02 |
| Revenue Next Year | $58.18 | $8.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 698.96 | 62.18 |
| 52 Week Low | $2.87 | $38.91 |
| 52 Week High | $9.75 | $147.03 |
| Indicator | NUVB | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 63.59 |
| Support Level | $5.28 | $56.50 |
| Resistance Level | $8.95 | $66.21 |
| Average True Range (ATR) | 0.37 | 2.10 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 62.35 | 77.96 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.